COMMUNIQUÉS West-GlobeNewswire

MitoRx Therapeutics presents new preclinical data on MTRX31, demonstrating restored mitochondrial density, at the 62nd EASD Annual Meeting
01/10/2026
MitoRx Therapeutics presents new preclinical data on MTRX31, demonstrating restored mitochondrial density, at the 62 nd EASD Annual Meeting MTRX31 shown to restore mitochondrial density in the liver of diet-induced [...]
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
01/10/2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
01/10/2026
Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, [...]
Allogenetics Appoints Dr. Olaf Schermeier as Chairman of the Advisory Board
01/10/2026
Hanover, Germany, October 01, 2026 – Allogenetics today announced the appointment of Olaf Schermeier, PhD, as Chairman of its Advisory Board. Dr. Schermeier brings more than 25 years of industry experience, including [...]
Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition
01/10/2026
In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in combination with a beneficial effect on body composition, with an increase in [...]
Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline
01/10/2026
Appointment brings extensive experience spanning drug discovery, translational medicine, clinical development and scientific leadership HORGEN, Switzerland, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Numab Therapeutics (“Numab [...]
DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform
01/10/2026
New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale Integrated AI models and workflows support better informed decisions about which antibodies to progress [...]
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
01/10/2026
In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in [...]
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
01/10/2026
Company announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people [...]
SkinHealth Systems Expands SkinStylus® SteriLock® MicroSystem to Europe
01/10/2026
Professional microneedling and nano-needling device launches in UK, Ireland, Germany, France, Spain and Portugal LONG BEACH, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems (Nasdaq: SKIN), home to flagship [...]
Le SkinStylus® SteriLock MicroSystem de SkinHealth Systems désormais disponible sur le marché européen
01/10/2026
Le dispositif professionnel de microneedling et de nanoneedling fait son entrée au Royaume-Uni, en Irlande, en Allemagne, en France, en Espagne et au Portugal LONG BEACH, Californie, 01 oct. 2026 (GLOBE NEWSWIRE) -- [...]
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
01/10/2026
Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG ( [...]
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
01/10/2026
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD Phase 1 study is evaluating the safety, tolerability and [...]
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
01/10/2026
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients [...]
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions
01/10/2026
New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals 1-3 Advanced AI-enabled analysis of imaging [...]
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
01/10/2026
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical [...]
IBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®
01/10/2026
IBA to offer QUANTM ® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics Louvain-la-Neuve, Belgium – October 1st, 2026, 7 a.m. – IBA (Ion [...]
IBA et Telix renforcent leur collaboration avec un accord de distribution de la technologie QIS® d’ARTMS
01/10/2026
IBA proposera le système d’irradiation QUANTM ® aux utilisateurs de cyclotrons partout dans le monde, afin d’accélérer la production locale de radio-métaux destinés à la théranostique. Louvain-la-Neuve, Belgique, 01 [...]
Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
01/10/2026
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1 -mutated populations, respectively, versus standard endocrine therapy plus everolimus 1 By targeting [...]

Pages